Telix Pharmaceuticals Limited

ASX:TLX Stock Report

Market Cap: AU$6.4b

Telix Pharmaceuticals Valuation

Is TLX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TLX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TLX (A$19.63) is trading below our estimate of fair value (A$41.67)

Significantly Below Fair Value: TLX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TLX?

Other financial metrics that can be useful for relative valuation.

TLX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.9x
Enterprise Value/EBITDA68.9x
PEG Ratio5.5x

Price to Sales Ratio vs Peers

How does TLX's PS Ratio compare to its peers?

The above table shows the PS ratio for TLX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average27.6x
RAC Race Oncology
50.5x-2.4%AU$311.7m
PYC PYC Therapeutics
23.1x9.3%AU$513.3m
CUV Clinuvel Pharmaceuticals
9.3x22.5%AU$777.7m
IMU Imugene
27.4x55.2%AU$418.9m
TLX Telix Pharmaceuticals
11.4x19.0%AU$6.4b

Price-To-Sales vs Peers: TLX is good value based on its Price-To-Sales Ratio (11.4x) compared to the peer average (27.6x).


Price to Earnings Ratio vs Industry

How does TLX's PE Ratio compare vs other companies in the AU Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.2%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.2%
n/an/an/a
No more companies

Price-To-Sales vs Industry: TLX is expensive based on its Price-To-Sales Ratio (11.4x) compared to the Australian Biotechs industry average (10.6x).


Price to Sales Ratio vs Fair Ratio

What is TLX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TLX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.4x
Fair PS Ratio13.8x

Price-To-Sales vs Fair Ratio: TLX is good value based on its Price-To-Sales Ratio (11.4x) compared to the estimated Fair Price-To-Sales Ratio (13.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TLX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$19.63
AU$20.87
+6.3%
15.4%AU$26.00AU$16.00n/a7
Jul ’25AU$18.09
AU$18.89
+4.4%
19.3%AU$26.00AU$13.90n/a7
Jun ’25AU$18.15
AU$17.47
-3.7%
22.5%AU$26.00AU$13.90n/a7
May ’25AU$14.67
AU$15.29
+4.2%
11.8%AU$19.30AU$13.52n/a7
Apr ’25AU$12.89
AU$14.88
+15.4%
12.1%AU$18.50AU$12.60n/a7
Mar ’25AU$11.93
AU$14.40
+20.7%
13.9%AU$18.50AU$12.43n/a7
Feb ’25AU$11.39
AU$13.47
+18.2%
10.4%AU$16.00AU$11.45n/a7
Jan ’25AU$10.08
AU$13.53
+34.3%
10.9%AU$16.00AU$11.45n/a7
Dec ’24AU$9.91
AU$13.37
+34.9%
8.1%AU$14.80AU$11.45n/a6
Nov ’24AU$8.98
AU$12.21
+35.9%
24.6%AU$14.80AU$5.26n/a7
Oct ’24AU$11.40
AU$12.38
+8.6%
24.4%AU$15.00AU$5.26n/a7
Sep ’24AU$10.80
AU$12.38
+14.6%
24.4%AU$15.00AU$5.26n/a7
Aug ’24AU$11.45
AU$12.20
+6.6%
24.2%AU$14.50AU$5.26n/a7
Jul ’24AU$11.22
AU$11.86
+5.7%
25.6%AU$14.50AU$5.26AU$18.097
Jun ’24AU$11.66
AU$10.99
-5.7%
28.2%AU$14.20AU$5.26AU$18.157
May ’24AU$10.46
AU$10.49
+0.3%
29.3%AU$14.20AU$5.26AU$14.676
Apr ’24AU$6.90
AU$9.68
+40.3%
18.2%AU$13.00AU$7.90AU$12.895
Mar ’24AU$6.77
AU$9.59
+41.6%
18.9%AU$13.00AU$7.90AU$11.935
Feb ’24AU$6.83
AU$9.32
+36.5%
20.1%AU$13.00AU$7.90AU$11.395
Jan ’24AU$7.27
AU$9.12
+25.4%
17.9%AU$12.30AU$7.90AU$10.085
Dec ’23AU$7.40
AU$9.12
+23.2%
17.9%AU$12.30AU$7.90AU$9.915
Nov ’23AU$7.00
AU$9.51
+35.9%
23.7%AU$13.50AU$7.37AU$8.986
Oct ’23AU$4.73
AU$9.24
+95.4%
25.2%AU$13.50AU$6.80AU$11.406
Sep ’23AU$5.91
AU$8.93
+51.1%
15.9%AU$11.30AU$6.89AU$10.806
Aug ’23AU$7.10
AU$8.92
+25.6%
13.4%AU$10.70AU$7.02AU$11.456
Jul ’23AU$4.64
AU$8.15
+75.6%
12.0%AU$10.00AU$6.88AU$11.226

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.